Source: Oleksandr.
  • Canopy Growth has signed subscription agreements with numerous institutions for a combined US$30 million investment
  • The funds, priced at US$4.29 per unit, will go towards general corporate purposes, paying down debt and strengthening the company’s working capital position
  • Canopy Growth is a North American cannabis and consumer packaged goods company with a brand portfolio including Doja, 7ACRES, Tweed, Deep Space, Martha Stewart CBD and Storz & Bickel
  • Canopy Growth stock opened with a loss of 9.05 per cent, trading at C$6.13 per share as of 9:40 am ET

Canopy Growth (TSX:WEED; NDAQ:CGC) has signed subscription agreements with numerous institutions for a combined US$30 million investment.

The company will sell 6,993,007 units priced at US$4.29 under a private placement and allocate the funds to general corporate purposes, paying down debt and bolstering its working capital position.

Each unit is composed of one Canopy Growth common share and one common share purchase warrant (either Series A or B). Each warrant allows the holder to purchase one common share for US$4.83. Series A warrants are immediately exercisable for five years after the closing of the offering, while Series B warrants are exercisable for five years only six months after the closing of the offering.

The company expects the private placement to close on Wednesday.

Investors interested in further due diligence should consult our extensive coverage of the cannabis stock, including:

Canopy Growth is a North American cannabis and consumer packaged goods company. Its brands include Doja, 7ACRES, Tweed, Deep Space, Martha Stewart CBD and Storz & Bickel.

The company has positioned itself to capitalize on U.S. cannabis legalization through its rights to Acreage Holdings, a vertically integrated multi-state cannabis operator, Wana Brands, a cannabis edibles brand, and Jetty Extracts, a producer of cannabis extracts and a pioneer of clean vape technology.

Canopy Growth stock (TSX:WEED) opened with a loss of 9.05 per cent, trading at C$6.13 per share as of 9:40 am ET. The stock has fallen by more than 80 per cent year-over-year and by more than 95 per cent since 2019.

Join the discussion: Find out what everybody’s saying about this cannabis stock on the Canopy Growth Bullboard, and check out the rest of Stockhouse’s stock forums and message boards.

The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.


More From The Market Online
Cannabis Report across cannabis plants

StockTalk | Cannabis Report: Shake-ups

MediPharm Labs announced that chief executive officer, David Pidduck will step down from his role, effective January...

Buzz on the Bullboards: As Arctic tensions flare, investors eye three news‑making stocks

Global markets opened the week on edge as a fresh rift between Washington and key NATO...

MediPharm Labs announces CEO transition as David Pidduck steps down

MediPharm Labs (TSX:LABS) CEO David Pidduck will step down on January 23, 2026, and will remain on the Board to support the transition.
Cannabis leaves with Stock Talk and Cannabis Report labels

StockTalk | Cannabis Report: New digs

Cannabis e-commerce company Herbal Dispatch (CSE:HERB) grew sales by 38 per cent in 2025, marking its third-straight year...